Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]

PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming BIO 2025 International Conference, to be held in ...